Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours

BACKGROUND: Overexpression of ErbB2 receptor in breast cancer is associated with disease progression and poor prognosis. Trastuzumab, the only humanised anti-ErbB2 antibody currently used in breast cancer, has proven to be effective; however, a relevant problem for clinical practice is that a high f...

Descripción completa

Detalles Bibliográficos
Autores principales: Gelardi, T, Damiano, V, Rosa, R, Bianco, R, Cozzolino, R, Tortora, G, Laccetti, P, D'Alessio, G, De Lorenzo, C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2822937/
https://www.ncbi.nlm.nih.gov/pubmed/20051960
http://dx.doi.org/10.1038/sj.bjc.6605499

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2822937/
https://www.ncbi.nlm.nih.gov/pubmed/20051960
http://dx.doi.org/10.1038/sj.bjc.6605499

Ejemplares similares